头皮银屑病发病机制和治疗的研究进展

doi:10.35541/cjd.20240001

Abstract

Abstract: 【Abstract】 The scalp is not only the most frequently affected area but also the primary site of psoriasis. It is notoriously challenging to treat due to its inherent resistance. The presence of distinct hair cycles and intricate microbial communities play a role in the development of unique lesions in scalp psoriasis. In recent years, significant progress has been made in the treatment of scalp psoriasis, with both biologics and small-molecule inhibitors proving to be effective. New topical therapies and phototherapy methods are also under exploration. This review summarizes the advancements in the pathogenesis and treatment for scalp psoriasis.

Key words: Psoriasis, Scalp dermatoses, Hair follicle, Drug therapy, Biological agents, Small molecule inhibitor, Phototherapy

Zhang Liangliang, Zhang Jiaan, Chen kun . Pathogenesis and treatment of scalp psoriasis[J]. Chinese Journal of Dermatology,2025,e20240001. doi:10.35541/cjd.20240001

References ［47］

［1］	胡煜, 顾恒, 陈崑. 中国中重度银屑病疾病负担和未满足治疗需求的系统综述［J］. 中华皮肤科杂志, 2023,56（10）:965⁃972. doi: 10.35541/cjd.20230063.
［2］	Camela E, Ocampo⁃Garza SS, Cinelli E, et al. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review［J］. Dermatol Ther, 2021,34（2）:e14857. doi: 10.1111/dth.14857.
［3］	Honma M, Hayashi K. Psoriasis: recent progress in molecular⁃targeted therapies［J］. J Dermatol, 2021,48（6）:761⁃777. doi: 10.1111/1346⁃8138.15727.
［4］	Committee of Psoriasis, Dermatology Branch, Chinese Medical Association.Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition#［J］.Int J Dermatol Venerol, 2020,3（1）:14⁃26. doi: 10.1097/JD9.0000000000000074.
［5］	Mosca M, Hong J, Hadeler E, et al. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management［J］. Dermatol Ther （Heidelb）, 2021,11（3）:769⁃797. doi: 10.1007/s13555⁃021⁃00521⁃z.
［6］	Zhang YJ, Sun YZ, Gao XH, et al. Integrated bioinformatic analysis of differentially expressed genes and signaling pathways in plaque psoriasis［J］. Mol Med Rep, 2019,20（1）:225⁃235. doi: 10.3892/mmr.2019.10241.
［7］	Brembilla NC, Senra L, Boehncke WH. The IL⁃17 family of cytokines in psoriasis: IL⁃17A and beyond［J］. Front Immunol, 2018,9:1682. doi: 10.3389/fimmu.2018.01682.
［8］	Ahn R, Yan D, Chang HW, et al. RNA⁃seq and flow⁃cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways［J］. Sci Rep, 2018,8（1）:11368. doi: 10.1038/s41598⁃018⁃29472⁃w.
［9］	Liu S, Zhuang Z, Liu F, et al. Identification of potential biomarkers and infiltrating immune cells from scalp psoriasis［J］. Gene, 2024,893:147918. doi: 10.1016/j.gene.2023.147918.
［10］	Suzuki T, Ito T, Gilhar A, et al. The hair follicle⁃psoriasis axis: shared regulatory mechanisms and therapeutic targets［J］. Exp Dermatol, 2022,31（3）:266⁃279. doi: 10.1111/exd.14462.
［11］	Lousada MB, Lachnit T, Edelkamp J, et al. Exploring the human hair follicle microbiome［J］. Br J Dermatol, 2021,184（5）:802⁃815. doi: 10.1111/bjd.19461.
［12］	Liu X, Cai Q, Yang H, et al. Distribution of Malassezia species on the skin of patients with psoriasis［J］. J Mycol Med, 2021,31（2）:101111. doi: 10.1016/j.mycmed.2021.101111.
［13］	Tao R, Wan Z, Li RY, et al. Integrated skin microbiome⁃metabolome analysis reveals altered bacterial community composition and metabolites in psoriasis［J］. Int J Dermatol Venereol, 2023，6（4）:181⁃188. doi: 10.1097/JD9.00000000000 00350.
［14］	Kayıran MA, Sahin E, Koçoğlu E, et al. Is cutaneous microbiota a player in disease pathogenesis? Comparison of cutaneous microbiota in psoriasis and seborrheic dermatitis with scalp involvement［J］. Indian J Dermatol Venereol Leprol, 2022,88（6）:738⁃748. doi: 10.25259/IJDVL_323_21.
［15］	Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for scalp psoriasis: summary of a cochrane systematic review［J］. Br J Dermatol, 2017,176（3）:604⁃614. doi: 10.1111/bjd.14811.
［16］	Ramic L, Sator P. Topical treatment of psoriasis vulgaris［J］. J Dtsch Dermatol Ges, 2023,21（6）:631⁃642. doi: 10.1111/ddg. 15042.
［17］	Gao JC, Emmerich VK, Feldman S, et al. Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and older［J］. Expert Opin Pharmacother, 2021,22（5）:543⁃547. doi: 10.1080/14656566.2020.1853099.
［18］	Kircik LH, Alonso⁃Llamazares J, Bhatia N, et al. Once⁃daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double⁃blind, vehicle⁃controlled phaseⅡb study［J］. Br J Dermatol, 2023,189（4）:392⁃399. doi: 10.1093/bjd/ljad182.
［19］	周玲慧. 抗人白介素⁃8单克隆抗体乳膏治疗头皮银屑病的疗效观察［D］.宁夏医科大学, 2022. doi: 10.27258/d.cnki.gnxyc. 2022.000096.
［20］	Heidemeyer K, Kulac M, Sechi A, et al. Lasers for the treatment of psoriasis: a systematic review［J］. Expert Rev Clin Immunol, 2023,19（7）:717⁃744. doi: 10.1080/1744666X.2023.2205640.
［21］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839.
［22］	Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for scalp psoriasis［J］. Cochrane Database Syst Rev, 2016,2（2）:CD009687. doi: 10.1002/14651858.CD009687.pub2.
［23］	Bagel J, Lynde C, Tyring S, et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double⁃blind, placebo⁃controlled study of etanercept［J］. J Am Acad Dermatol, 2012,67（1）:86⁃92. doi: 10.1016/j.jaad.2011.07.034.
［24］	Fotiadou C, Lazaridou E, Sotiriou E, et al. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre［J］. J Eur Acad Dermatol Venereol, 2016,30（12）:2091⁃2096. doi: 10.1111/jdv.13780.
［25］	Noda S, Mizuno K, Adachi M. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community⁃based hospital［J］. J Dermatol, 2012,39（3）:265⁃268. doi: 10.1111/j.1346⁃8138.2011.01312.x.
［26］	Thaçi D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study［J］. J Eur Acad Dermatol Venereol, 2015,29（2）:353⁃360. doi: 10.1111/jdv.12553.
［27］	Khobzey K, Liskova I, Szegedi A, et al. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice［J］. Acta Dermatovenerol Alp Pannonica Adriat, 2017,26（1）:11⁃14. doi: 10.15570/actaapa.2017.3.
［28］	Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate⁃to⁃severe scalp psoriasis: results of a 24⁃week, randomized, double⁃blind, placebo⁃controlled phase 3b study［J］. J Am Acad Dermatol, 2017,77（4）:667⁃674. doi: 10.1016/j.jaad.2017.05.033.
［29］	Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate⁃to⁃severe psoriasis, including scalp and palmoplantar psoriasis: a 104⁃week clinical study［J］. Dermatol Ther, 2019,32（5）:e13006. doi: 10.1111/dth.13006.
［30］	Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate⁃to⁃severe psoriasis with scalp involvement: results from three phase 3 trials （UNCOVER⁃1, UNCOVER⁃2, UNCOVER⁃3）［J］. J Dermatolog Treat, 2017,28（4）:282⁃287. doi: 10.1080/09546634.2016.1249820.
［31］	Langley RG, Papp K, Gooderham M, et al. Efficacy and safety of continuous every⁃2⁃week dosing of ixekizumab over 52 weeks in patients with moderate⁃to⁃severe plaque psoriasis in a randomized phaseⅢ trial （IXORA⁃P）［J］. Br J Dermatol, 2018,178（6）:1315⁃1323. doi: 10.1111/bjd.16426.
［32］	Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2015,29（9）:1763⁃1770. doi: 10.1111/jdv.12996.
［33］	Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials［J］. J Dermatolog Treat, 2022,33（1）:261⁃265. doi: 10. 1080/09546634.2020.1749546.
［34］	Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti⁃interleukin⁃17⁃receptor antibody in the treatment of Japanese patients with moderate⁃to⁃severe plaque psoriasis: efficacy and safety results from a phaseⅡ randomized controlled study［J］. J Dermatol Sci, 2016,81（1）:44⁃52. doi: 10.1016/j.jdermsci.2015. 10.009.
［35］	Kokolakis G, Ghoreschi K. The clinical significance of simultaneous IL⁃17A and IL⁃17F blockade in psoriasis non⁃responding to anti⁃IL17A therapy［J］. J Clin Med, 2022,12（1）:35. doi: 10.3390/jcm12010035.
［36］	Megna M, Picone V, Ventura V, et al. A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab［J］. JAAD Case Rep, 2023,38:123⁃126. doi: 10.1016/j.jdcr.2023.05.043.
［37］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phaseⅢ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［38］	Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phaseⅢ, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial［J］. J Am Acad Dermatol, 2017,76（3）:418⁃431. doi: 10.1016/j.jaad.2016. 11.042.
［39］	Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult⁃to⁃treat areas: scalp, nail, palmoplantar and genital psoriasis［J］. J Clin Med, 2022,11（9）:2631. doi: 10.3390/jcm11092631.
［40］	Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med, 2017,376（16）:1551⁃1560. doi: 10.1056/NEJMoa1607017.
［41］	Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab （LY3074828） in the treatment of moderate⁃to⁃severe plaque psoriasis: results from a randomized phaseⅡ study［J］. Br J Dermatol, 2019,181（1）:88⁃95. doi: 10.1111/bjd.17628.
［42］	Orsini D, Gargiulo L, Ibba L, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult⁃to⁃treat areas: a real⁃world experience from two referral centers［J］. J Dermatolog Treat, 2023,34（1）:2220849. doi: 10.1080/09546634.2023.2220849.
［43］	王玲艳, 潘靖, 苗钢, 等. 对生物制剂治疗抵抗的银屑病患者皮损部位分析［J］. 中华皮肤科杂志, 2022,55（7）:583⁃587. doi: 10.35541/cjd.20220133.
［44］	Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis［J］. Drugs, 2017,77（4）:459⁃472. doi: 10.1007/s40265⁃017⁃0709⁃1.
［45］	Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis［J］. J Am Acad Dermatol, 2024,90（4）:775⁃782. doi: 10.1016/j.jaad.2023.11.060.
［46］	王茜, 孙雪淞, 张丽宏, 等. 中药外治法治疗头皮型银屑病的Meta分析［J］. 云南中医中药杂志, 2023,44（1）:31⁃37. doi: 10.3969/j.issn.1007⁃2349.2023.01.010.
［47］	黄强, 龚丽萍. 头皮银屑病的中西医结合治疗进展［J］. 江西中医药, 2021,52（1）:75⁃77.

[1]	Shi Rongcan¹, ², Yu Zengyang², ³, Luo Qingqiong², Ma Rui¹, ², Jiang Xingyu¹, ², Wang Yuanyuan¹, ², Cai Jiangluyi¹, ², Shi Yuling¹, ². Palmitoyl-proteomic profiles of psoriatic lesions and their role in inflammatory responses: a preliminary study [J]. Chinese Journal of Dermatology, 2026, 59(8): 738-749.
[2]	Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （ edition）”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727.
[3]	Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases [J]. Chinese Journal of Dermatology, 2026, 59(7): 671-674.
[4]	Yuwen Tianyi¹, Zhou Zizhen¹, Tian Jingyu¹, Chen Sihan², Li Min², Zhang Fengyuan¹, Gu Heng, ², Chen Xu, ². Expression of the glutaminase 1/ammonia metabolism axis in keratinocytes in ultraviolet B-induced acute skin injury and psoriatic skin inflammation [J]. Chinese Journal of Dermatology, 2026, 59(7): 654-661.
[5]	Hu Yu, Lu Yan, Chen Kun, Gu Heng. Standardization, precision, and full-cycle management: interpretation of Specifications for the Management of Vitiligo Patients Undergoing Home Phototherapy [J]. Chinese Journal of Dermatology, 2026, 59(7): 632-636.
[6]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2026, 59(5): 459-463.
[7]	Chen Tingnan, Liang Jingyao, Deng Shilin, Shu Zhirong, Zhang Xibao. Immunophenotypic switching between psoriasis and atopic dermatitis after biologic therapy: a systematic review of clinical features, mechanisms and management strategies [J]. Chinese Journal of Dermatology, 2026, 59(5): 474-481.
[8]	Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema: a case-series study [J]. Chinese Journal of Dermatology, 2026, 59(5): 464-467.
[9]	Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment and rehabilitation of psoriasis in the elderly （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 407-418.
[10]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Dermatology Branch of China Alliance for Rare Diseases. Expert consensus on fecal microbiota transplantation in the treatment of psoriasis （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 427-435.
[11]	Zhou Yuting, Song Qinghua, Wang Wenhui. Susceptibility genes of generalized pustular psoriasis [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240211-e20240211.
[12]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on management of psoriasis with comorbidities （2026） [J]. Chinese Journal of Dermatology, 2026, 59(3): 193-207.
[13]	Wang Juncheng, Liu Jie. Artificial intelligence in psoriasis: diagnosis, treatment and patient management [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240061-e20240061.
[14]	Guo Lan, Jin Hongzhong. Tryptophan and arginine metabolism in immune regulation and their role in the pathogenesis of psoriasis [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240377-e20240377.
[15]	Yan Shiyi, Suo Huinan, Tao Juan, Zhou Nuoya. Role of mechanical tension in the development of skin diseases [J]. Chinese Journal of Dermatology, 2026, 0(3): 20230638-e20230638.

Pathogenesis and treatment of scalp psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［47］

Related Articles 15

Metrics

Comments

Recommended 10